Witjes WPJ - Search Results

1

Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.

Boevé LMS, Hulshof MCCM, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, Delaere KPJ, Moorselaar RJAV, Verhagen PCMS, van Andel G. Boevé LMS, et al. Among authors: witjes wpj. Eur Urol. 2019 Mar;75(3):410-418. doi: 10.1016/j.eururo.2018.09.008. Epub 2018 Sep 25. Eur Urol. 2019. PMID: 30266309 Clinical Trial.

2

Prostate-specific antigen density: correlation with histological diagnosis of prostate cancer, benign prostatic hyperplasia and prostatitis.

van Iersel MP, Witjes WP, de la Rosette JJ, Oosterhof GO. van Iersel MP, et al. Br J Urol. 1995 Jul;76(1):47-53. doi: 10.1111/j.1464-410x.1995.tb07830.x. Br J Urol. 1995. PMID: 7544204 Free article.

3

The value of neoadjuvant therapy in localized prostate cancer.

Witjes WP, Oosterhof GO, Schaafsma HE, Debruyne FM. Witjes WP, et al. Int J Urol. 1995 Mar;2(1):1-5. doi: 10.1111/j.1442-2042.1995.tb00611.x. Int J Urol. 1995. PMID: 7614403 Free article. Review. No abstract available.

4

Risk factors in carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.

van Gils-Gielen RJ, Witjes WP, Caris CT, Debruyne FM, Witjes JA, Oosterhof GO. van Gils-Gielen RJ, et al. Urology. 1995 Apr;45(4):581-6. doi: 10.1016/s0090-4295(99)80047-8. Urology. 1995. PMID: 7716838 Clinical Trial.

5

A multicentre trial of combined neoadjuvant androgen blockade with Zoladex and flutamide prior to radical prostatectomy in prostate cancer. The European Study Group on Neoadjuvant Treatment.

Debruyne FM, Witjes WP, Schulman CC, van Cangh PJ, Oosterhof GO. Debruyne FM, et al. Eur Urol. 1994;26 Suppl 1:4. doi: 10.1159/000475423. Eur Urol. 1994. PMID: 7737257 Clinical Trial. No abstract available.

6

Overview of current status of total androgen deprivation in metastasized prostate cancer.

Debruyne FM, Witjes WP. Debruyne FM, et al. Eur Urol. 1993;24 Suppl 2:67-71. Eur Urol. 1993. PMID: 8262129 Review.

7

Neoadjuvant therapy in prostate cancer--is it of any use?

Witjes WP, Horenblas S, Oosterhof GO, Schaafsma HE, Debruyne FM. Witjes WP, et al. Eur Urol. 1993;24(4):433-7. doi: 10.1159/000474346. Eur Urol. 1993. PMID: 8287884 Review.

8

Overview of the current status of total androgen deprivation in metastasized prostate cancer.

Debruyne FM, Witjes WP. Debruyne FM, et al. World J Urol. 1993;11(4):233-6. doi: 10.1007/BF00185076. World J Urol. 1993. PMID: 8312942 Review. No abstract available.

9

Urodynamic and clinical effects of terazosin therapy in patients with symptomatic benign prostatic hyperplasia.

Witjes WP, Rosier FW, de Wildt MJ, van Iersel MP, Debruyne FM, de La Rosette JJ. Witjes WP, et al. J Urol. 1996 Apr;155(4):1317-23. J Urol. 1996. PMID: 8632523 Clinical Trial.

10

Variability of clinical and pressure-flow study variables after 6 months of watchful waiting in patients with lower urinary tract symptoms and benign prostatic enlargement.

Witjes WP, de Wildt MJ, Rosier PF, Caris CT, Debruyne FM, de la Rosette JJ. Witjes WP, et al. J Urol. 1996 Sep;156(3):1026-34. J Urol. 1996. PMID: 8709301

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

77 results

Search Page

Filters